Checkpoint Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 10

  • Investments
  • 1

Checkpoint Therapeutics General Information

Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Contact Information

Website
www.checkpointtx.com
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 95 Sawyer Road
  • Suite 110
  • Waltham, MA 02453
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 95 Sawyer Road
  • Suite 110
  • Waltham, MA 02453
  • United States
+1 (781)

Checkpoint Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Checkpoint Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Checkpoint Therapeutics‘s full profile, request access.

Request a free trial

Checkpoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisit
Biotechnology
Waltham, MA
24 As of 2024

Gaithersburg, MD
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Checkpoint Therapeutics Competitors (50)

One of Checkpoint Therapeutics’s 50 competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altimmune Formerly VC-backed Gaithersburg, MD
Omeros Formerly VC-backed Seattle, WA
ABIONYX Pharma Formerly VC-backed Balma, France
XBiotech Corporation Austin, TX
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
You’re viewing 5 of 50 competitors. Get the full list »

Checkpoint Therapeutics Patents

  • 18

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Checkpoint Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022120008-A Pd-l1 specific antibodies and methods of using same Active 29-Jun-2016
AU-2017290709-A1 Pd-l1-specific antibodies and methods of using the same Active 29-Jun-2016
AU-2017290709-B2 Pd-l1-specific antibodies and methods of using the same Active 29-Jun-2016
AU-2024227032-A1 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016
CA-3027204-A1 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016 C07K16/2827
To view Checkpoint Therapeutics’s complete patent history, request access »

Checkpoint Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Checkpoint Therapeutics Investments (1)

Checkpoint Therapeutics’s most recent deal was a Corporate Asset Purchase with NeuPharma (Worldwide License to CK-101).

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NeuPharma (Worldwide License to CK-101) Corporate Asset Purchase Buildings and Property
To view Checkpoint Therapeutics’s complete investments history, request access »

Checkpoint Therapeutics FAQs

  • When was Checkpoint Therapeutics founded?

    Checkpoint Therapeutics was founded in 2014.

  • Where is Checkpoint Therapeutics headquartered?

    Checkpoint Therapeutics is headquartered in Waltham, MA.

  • What is the size of Checkpoint Therapeutics?

    Checkpoint Therapeutics has 24 total employees.

  • What industry is Checkpoint Therapeutics in?

    Checkpoint Therapeutics’s primary industry is Biotechnology.

  • Is Checkpoint Therapeutics a private or public company?

    Checkpoint Therapeutics is a Private company.

  • What is the current valuation of Checkpoint Therapeutics?

    The current valuation of Checkpoint Therapeutics is .

  • What is Checkpoint Therapeutics’s current revenue?

    The current revenue for Checkpoint Therapeutics is .

  • How much funding has Checkpoint Therapeutics raised over time?

    Checkpoint Therapeutics has raised $139M.

  • Who are Checkpoint Therapeutics’s competitors?

    Altimmune, Omeros, ABIONYX Pharma, XBiotech, and Vertex Pharmaceuticals are some of the 50 competitors of Checkpoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process